This message contains My NCBI what's new results from the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM).
Do not reply directly to this message.
Sender's message:
Sent on Tuesday, 2010 May 18Search kinetoplastids OR kinetoplastid OR Kinetoplastida OR "trypanosoma brucei" OR leishmania OR brucei OR leishmaniasis OR "African trypanosomiasis"
Click here to view complete results in PubMed. (Results may change over time.)
To unsubscribe from these e-mail updates click here.
| PubMed Results |
| 1. | Bioorg Med Chem. 2010 Apr 28. [Epub ahead of print]Synthesis and in vitro antiprotozoal evaluation of substituted phenalenone analogues.Rosquete LI, Cabrera-Serra MG, Piñero JE, Martín-Rodríguez P, Fernández-Pérez L, Luis JG, McNaughton-Smith G, Abad-Grillo T.Instituto Universitario de Bio-Orgánica 'Antonio González', Universidad de La Laguna, Avda. Fco., Sánchez 2, 38206 La Laguna, Tenerife, Canary Islands, Spain. AbstractA set of derivatives encompassing structural modifications on the privileged phenalenone scaffold were assessed for their antiparasitic activities against the most clinically relevant forms of trypanosomiasis and leishmaniasis. Several compounds exhibited leishmanicidal effects at levels comparable or better than the reference drug pentamidine, while the parent phenalenone was shown to have a level of activity against Trypanosoma cruzi comparable to the marketed drug benznidazole. Copyright © 2010 Elsevier Ltd. All rights reserved. |
| PMID: 20472446 [PubMed - as supplied by publisher] | |
| Related citations | |
| 2. | Vaccine. 2010 May 13. [Epub ahead of print]Serine proteases of Leishmani a amazonensis as immunomodulatory and disease-aggravating components of the crude LaAg vaccine.de Matos Guedes HL, Pinheiro RO, Chaves SP, de-Simone SG, Rossi-Bergmann B.Laboratório de Imunofarmacologia, Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, 21941-902 Rio de Janeiro, RJ, Brazil; Laboratório de Bioquímica de Proteínas e Peptídeos, Departamento de Bioquímica e Biologia Molecular, Fundação Oswaldo Cruz, Rio de Janeiro, RJ, Brazil. AbstractWe previously demonstrated that intradermal and intramuscular vaccination with Leishmania amazonensis promastigote antigens (LaAg) increases the susceptibility of BALB/c mice to cutaneous leishmaniasis. In this study, we investigated the role played by serine and cysteine proteases as disease-promoting components of LaAg. Mice were immunized by the intramuscular route with LaAg that was pre-treated with a pool of serine or cysteine protease inhibitors (SPi and CPi, respectively) prior to infection with L. amazonensis. Neutralization of either enzyme type reversed the disease-promoting effect of LaAg, as seen by the slower lesion development. However, the parasite burden was only effectively controlled in mice receiving SPi-treated LaAg. Protection was associated with diminished production of TGF-beta and particularly IL-10 in response to parasite antigens by the lesion-draining lymph node cells of vaccinated mice relative to control. In vitro, soluble proteases isolated from LaAg (LaSP-Sol) directly activated IL-4, IL-10 and TGF-beta production by immune cells. Like native LaAg, vaccination with LaSP-Sol primed mice to respond to parasite challenge with a strong Jones-Mote cutaneous hypersensitivity reaction, and increased susceptibility to infection. Furthermore, neutralization of serine but not cysteine proteases blocked the capacity of LaAg to sensitize mice for Jones-Mote reaction. Together, these results indicate that soluble serine proteases are key components of LaAg responsible for its disease-promoting immunity. Copyright © 2010. Published by Elsevier Ltd. |
| PMID: 20472030 [PubMed - as supplied by publisher] | |
| Related citations | |
| 3. | Vet Clin North Am Small Anim Pract. 2010 May;40(3):409-23.Immunodeficiencies caused by inf ectious diseases.Sykes JE.Department of Medicine & Epidemiology, University of California-Davis, CA 95616, USA. jesykes@ucdavis.edu AbstractImmunodeficiencies caused by infectious agents may result from disruption of normal host barriers or dysregulation of cellular immunity, the latter serving to promote survival of the infectious agent through immune evasion. Such infections may be followed by opportunistic infections with a variety of other microorganisms. Classic infectious causes of immunodeficiency in companion animals are the immunodeficiency retroviruses, including feline immunodeficiency virus and feline leukemia virus. Other important causes include canine distemper virus; canine parvovirus 2; feline infectious peritonitis virus; rickettsial organisms that infect leukocytes; Leishmania; and fungal pathogens, such as Cryptococcus. Considerable research effort has been invested in understanding the mechanisms of pathogen-induced immunosuppression, with the hope that effective therapies may be developed that reverse the immunodeficiencies developed and in turn assist the host to clear persistent or life-threatening infectious diseases. Published by Elsevier Inc. |
| PMID: 20471525 [PubMed - in process] | |
| Related citations | |
| 4. | Mol Biochem Parasitol. 2010 May 11. [Epub ahead of print]YCF 45 protein, usually associated with plastids, is targeted into the mitochondrion of Trypanosoma brucei.Týč J, Long S, Jirků M, Lukeš J.Biology Centre, Institute of Parasitology and Faculty of Sciences, University of South Bohemia, Ceské Budejovice (Budweis), Czech Republic. AbstractYCF45 belongs to a family of proteins of unknown function usually located in the chloroplast of plants. Its highly conserved homologues were found in the genomes of several Trypanosoma and Leishmania species. HA(3)-tagging of the YCF45 protein with the start codon as annotated in the Gene(DB) revealed its cytosolic localization in the cultured procyclic stage of Trypanosoma brucei. However, when a more upstream located start codon was used in another HA(3)-tagged construct, the resulting protein was targeted to the mitochondrion. We propose that YCF45 was acquired by an ancestral trypanosomatid by horizontal gene transfer and in the absence of a plastid was re-targeted to the mitochondrion. Copyright © 2010. Published by Elsevier B.V. |
| PMID: 20470834 [PubMed - as supplied by publisher] | |
| Related citations | |
| 5. | Rev Bras Parasitol Vet. 2009 Dec;18 Suppl 1:49-53.[Factors associated the seropositivity for Babesia, Toxoplasma, Neospora e Leishmania in dogs attended at nine veterinary clinics in the municipality of Lavras, MG][Article in Portuguese] Guimarães AM, Rocha CM, Oliveira TM, Rosado IR, Morais LG, Santos RR.Departamento de Medicina Veterinária, Universidade Federal de Lavras-UFLA, Campus Universitário, CP 3037, CEP 37200-000 Lavras-MG, Brazil. amg@ufa.br AbstractThe aim of the present study was to determine the frequency and evaluate the infuence of age, sex and breed in seropositivity anti-Babesia canis, Toxoplasma gondii, Leishmania (L.) chagasi and Neospora caninum, by means of the indirect immunofuorescence antibody test (IFAT), in serum samples collected from dogs attended in nine private veterinary clinics in municipality of Lavras, Minas Gerais, Brazil, from August 2000 to April 2002. Of 300 dogs, 73.3% were seropositive (IFAT>or=1:80) to B. canis, and there was a signifcant increase (p<0.05) of the reagent in adult animals when compared with young. Only one dog (0.3%) from Belo Horizonte there was antibodies anti-L. (L.) chagasi (IFAT>or=1:40). T. gondii, of 218 dogs, 60.7% were positive (IFAT>or=1:16). In 228 serum samples, 3.1% were positive (IFAT>or=1:50) to N. caninum. Infections to B. canis and T. gondii occur as endemic form in dogs examined at private veterinary clinics in Lavras. Tere is no evidence that there are autochthonous cases of canine visceral leishmaniosis in Lavras. Besides this the infection by N. caninum is uncommon in dogs breed at the urbane zone of the municipality. |
| PMID: 20040191 [PubMed - in process] | |
| Related citations | |
Publication Types:
|
| 6. | Adv Drug Deliv Rev. 2010 Mar 18;62(4-5):576-88. Epub 2009 Nov 23.Nanotechnological approaches against Chagas disease.Romero EL, Morilla MJ.Programa de Nanomedicinas, Universidad Nacional de Quilmes, Bernal, Buenos Aires, Argentina. elromero@unq.edu.ar AbstractOver several thousand years, the flagellated Trypanosome cruzi-causative agent of Chagas disease-developed a complex life cycle between the reduviidae vectors and its human hosts. Due to their silent and hidden location, the intracellular amastigotes are mainly responsible for the nearly 50,000 annual deaths caused by the chronic chagasic cardiomyopathy. Chagas disease is the most important parasitic disease in the Americas, though treatments have not evolved towards a more efficient pharmacotherapy that (i) eradicates the scarce amastigotes present at the indeterminate/chronic form and (ii) employs less toxic drugs than benznidazole or nifurtimox. Nano-drug delivery systems (nanoDDS) represent useful means to selectively deliver the drug to intracellular targets. However, preclinical research in Chagas must be extended in order to improve the chances of a clinical implementation. The stages involved in this process are (i) selection of the appropriate drug for a specific parasite, (ii) development of a drug-loaded nanoDDS structure that displays the adequate pharmacokinetics, biodistribution and intracellular transit and (iii) selection of the right parasite form to target and the right stage of the disease for the treatment to be started. In this review we will critically overview the few research works published in the last 20years in the context of nanotechnology and Chagas diseases and highlight the gaps in knowledge towards the design of more efficient medicines to address this endemic. Copyright 2009 Elsevier B.V. All rights reserved. |
| PMID: 19941920 [PubMed - indexed for MEDLINE] | |
| Related citations | |
Publication Types:
MeSH Terms:
Substances:
|
No comments:
Post a Comment